Physician profile
Dal Chun
NPI 1578587135
$12,308.90
in general payments reported to CMS, 2019-2025
17 companies · $10K in 2025
The $10K reported for 2025 was more than what 90% of Retina Specialist providers received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $193 · 2020: $217 · 2021: $358 · 2022: $284 · 2023: $593 · 2024: $552 · 2025: $10K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $8,460 · Food and Beverage: $1,944 · Travel and Lodging: $854.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $8,460.00 |
| Food and Beverage | $1,944.00 |
| Travel and Lodging | $853.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Pharmaceuticals, INC. | $9,610.94 | 2024-2025 | Eylea Hd |
| Astellas Pharma US INC | $376.72 | 2023-2025 | Izervay |
| Genentech USA, INC. | $368.60 | 2021-2025 | Vabysmo |
| Abbvie INC. | $355.49 | 2022-2025 | Ozurdex |
| Alimera Sciences, INC. | $293.22 | 2021-2023 | Iluvien |
| Regeneron Healthcare Solutions, INC. | $261.62 | 2022-2025 | Eylea Hd |
| Apellis Pharmaceuticals, INC. | $243.20 | 2023-2025 | Syfovre |
| Allergan, INC. | $238.48 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $124.75 | 2019-2021 | |
| Alcon Vision LLC | $119.76 | 2020 | |
| Bausch & Lomb Americas INC. | $84.31 | 2022-2023 | Xipere, Prolensa, Lotemax Sm |
| Eyepoint US, INC. | $62.29 | 2019-2022 | |
| Kala Pharmaceuticals, INC. | $50.34 | 2021-2022 | |
| Ani Pharmaceuticals, INC. | $34.72 | 2025 | Iluvien |
| Neurotech Pharmaceuticals, INC. | $34.56 | 2025 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coherus Oncology, INC. | $28.95 | 2023 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $20.95 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dal Chun listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.